Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · IEX Real-Time Price · USD
22.57
-0.48 (-2.08%)
At close: Jul 2, 2024, 4:00 PM
22.08
-0.49 (-2.17%)
Pre-market: Jul 3, 2024, 4:37 AM EDT
Beam Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Beam Therapeutics stock have an average target of 42.2, with a low estimate of 30 and a high estimate of 57. The average target predicts an increase of 86.97% from the current stock price of 22.57.
Analyst Consensus: Buy
* Price targets were last updated on May 8, 2024.
Analyst Ratings
The average analyst rating for BEAM stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 3 | 3 | 3 | 4 | 4 | 4 |
Hold | 6 | 6 | 5 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 10 | 10 | 9 | 10 | 10 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Barclays | Barclays | Hold Maintains $42 → $33 | Hold | Maintains | $42 → $33 | +46.21% | May 8, 2024 |
Wedbush | Wedbush | Buy Reiterates $57 | Buy | Reiterates | $57 | +152.55% | Apr 23, 2024 |
BMO Capital | BMO Capital | Buy Maintains $57 | Buy | Maintains | $57 | +152.55% | Mar 27, 2024 |
Barclays | Barclays | Hold Maintains $26 → $42 | Hold | Maintains | $26 → $42 | +86.09% | Feb 28, 2024 |
RBC Capital | RBC Capital | Hold Maintains $27 → $35 | Hold | Maintains | $27 → $35 | +55.07% | Feb 28, 2024 |
Financial Forecast
Revenue This Year
51.12M
from 377.71M
Decreased by -86.47%
Revenue Next Year
49.19M
from 51.12M
Decreased by -3.77%
EPS This Year
-4.85
from -1.72
EPS Next Year
-4.85
from -4.85
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 84.0M | 115.5M | 168.0M | 135.5M | 467.3M |
Avg | 51.1M | 49.2M | 49.1M | 83.5M | 221.1M |
Low | 7.3M | n/a | n/a | 29.5M | 68.8M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -77.8% | 125.9% | 241.5% | 175.9% | 459.5% |
Avg | -86.5% | -3.8% | -0.2% | 70.1% | 164.7% |
Low | -98.1% | - | - | -39.9% | -17.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -4.06 | -3.47 | -2.90 | -3.42 | -1.65 |
Avg | -4.85 | -4.85 | -4.70 | -4.47 | -3.46 |
Low | -5.05 | -5.54 | -6.12 | -5.92 | -5.79 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.